TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05145972

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Superior Hypogastric Plexus
Description: The division of abdominal aorta into common iliac arteries will be identified by using longitudinal sonography , and the body of the fifth (5th) Lumbar vertebra will be identified by placing the transducer transversely. A skin wheal will be raised with subcutaneous infiltration with 2% lidocaine solution nearly 3-4 cm below the umbilicus. A 15-cm Long 22-G Chiba needle will be used with out of plane technique, and the needle will be advanced under USG-guidance to reach the anterior- most point of the fifth Lumber vertebral body avoiding the vascular structures. The needle will be withdrawn nearly 1-2 mm after hitting the vertebral body to avoid injecting the drug into the periosteum. After confirming a negative aspiration of blood, known amount of neurolytic agent according to the grouping will be injected for the neurolysis of superior hypogastric plexus. The uniform spread of the drug will be confirmed under real-time sonography.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Superior Hypogastric Plexus
Description: The division of abdominal aorta into common iliac arteries will be identified by using longitudinal sonography , and the body of the fifth (5th) Lumbar vertebra will be identified by placing the transducer transversely. A skin wheal will be raised with subcutaneous infiltration with 2% lidocaine solution nearly 3-4 cm below the umbilicus. A 15-cm Long 22-G Chiba needle will be used with out of plane technique, and the needle will be advanced under USG-guidance to reach the anterior- most point of the fifth Lumber vertebral body avoiding the vascular structures. The needle will be withdrawn nearly 1-2 mm after hitting the vertebral body to avoid injecting the drug into the periosteum. After confirming a negative aspiration of blood, known amount of neurolytic agent according to the grouping will be injected for the neurolysis of superior hypogastric plexus. The uniform spread of the drug will be confirmed under real-time sonography.
Study: NCT05166096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rho-11
Description: Subjects will be administered 325 mg aspirin by rapid IV push

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rho-11
Description: Subjects will be administered 325 mg aspirin by rapid IV push

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 325mg
Description: Subjects will be administered 325 mg aspirin orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 325mg
Description: Subjects will be administered 325 mg aspirin orally
Study: NCT05230732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromodulation device
Description: Active LLTS will be performed by use of a neuromodulation device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 12 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Sham LLTS will be performed by use of a neuromodulation device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour daily for 12 weeks
Study: NCT01014676

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05055596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Qigong/Tai Chi Easy is a manualized intervention with formal training for instructors through the Institute of Integral Qigong and Tai Chi (IIQTC). The protocol can be modified based on participant needs and physical abilities. Qigong/Tai Chi Easy uses a series of repeated and simple-to-learn movements (rather than long forms with complicated choreography).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Coaching
Description: The Health Education group will be adapted from a previously developed time and attention control condition used in HIV research. Additional health education material will be based on information learned in the qualitative interviews conducted prior to the start of this study. Examples of session material include the following: sleep hygiene, healthy diet, sun safety, and healthy homes.
Study: NCT05179629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: M TAPA block
Description: Under aseptic conditions, a high frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with totally 30 ml (15 ml for each side) of %0,25 bupivacaine.
Study: NCT05672056

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer guided placement of a stock plate pre-bent on a 3D printed model
Description: We aim to design a novel guide that can secure the construct of the fibular segments and pre bent plate onto the native mandible and effectively and efficiently translate the VSP into the surgical field.
Study: NCT05251870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70
Description: Intranodal administration into an inguinal lymphnode. Two administrations at the same injection site with a four week interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70
Description: Intranodal administration into an inguinal lymphnode. Two administrations at the same injection site with a four week interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70
Description: Intranodal administration into an inguinal lymphnode. Two administrations at the same injection site with a four week interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70
Description: Intranodal administration into an inguinal lymphnode. Two administrations at the same injection site with a four week interval.
Study: NCT06272097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention program based on TIME-CDST tool led by wound specialist nurses
Description: Based on the TIME CDST tool led by wound specialist nurses, which includes the following four areas: A. Assess patient, well-being and wound; B. Bring in multidisciplinary team and informal carers to promote holistic patient care; C. Control or treat underlying causes and barriers to wound healing; D. Decide appropriate treatment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A routine wound care program
Description: A routine wound care program of wound cleaning and dressing changes
Study: NCT04708587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dual anti-platelet therapy at least 6 months
Description: Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months after randomization. Clopidogrel or prasugrel should be maintained after 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dual anti-platelet therapy 3months or less
Description: Patient enrolled in the dual antiplatelet therapy less than 3 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for less than 3 months after randomization. After 3 months clopidogrel or prasugrel should be maintained.
Study: NCT06399315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134 or placebo
Description: The patients will receive ZE46-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134 or placebo
Description: The patients will receive ZE46-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134 or placebo
Description: The patients will receive ZE46-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134 or placebo
Description: The patients will receive ZE46-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134 or placebo
Description: The patients will receive ZE46-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134 or placebo
Description: The patients will receive ZE46-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134 or placebo
Description: The patients will receive ZE46-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE46-0134 or placebo
Description: The patients will receive ZE46-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole, 20mg oral
Description: Rabeprazole 20 mg daily will be administered for 2 prior ZE46-0134 and 7 co-administered
Study: NCT05519631

Intervention type: OTHER
Intervention: electroencephalogram
Description: The EEG is the recording of electrical activity in the brain in different regions of the cortex. The capture of electrical signals is performed by attaching electrodes to the surface of the scalp. As the EEG signal has an amplitude in microvolts (µVpp) it is necessary to use amplifiers, leaving the signal possible to be registered. The electrode-electrolyte interface is very important and must be able to provide a good connection between the skin and the conductive material of the electrode, otherwise the EEG signal, in addition to being contaminated by noise, may suffer distortion.
Study: NCT06238063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Advance Care Planning (ACP) Intervention
Description: An ACP discussion between the participating resident, family members, and the trained nurse will be incorporated into the annual review. The proposed ACP intervention will be divided into three parts (three weekly sessions, 1.5 hours each): 1) preparatory, 2) discussion, and 3) follow-up sessions.
Study: NCT05272423

Intervention type: DIAGNOSTIC_TEST
Intervention: FoundationOne® Liquid CDx
Description: The FoundationOne® Liquid CDx is an FDA-approved companion diagnostic that analyzes guideline-recommended genes from a simple blood draw.

Intervention type: DIAGNOSTIC_TEST
Intervention: FoundationOne® Liquid CDx
Description: The FoundationOne® Liquid CDx is an FDA-approved companion diagnostic that analyzes guideline-recommended genes from a simple blood draw.
Study: NCT05733819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subject-specific optimized RAS
Description: Walking with metronome-based RAS cueing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Walking
Description: Walking without RAS cueing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Walking
Description: Walking without RAS cueing
Study: NCT06077669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Single oral dose of methylphenidate (5mg or 10 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Single oral dose of methylphenidate (5mg or 10 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo
Study: NCT05519631

Intervention type: OTHER
Intervention: electroencephalogram
Description: The EEG is the recording of electrical activity in the brain in different regions of the cortex. The capture of electrical signals is performed by attaching electrodes to the surface of the scalp. As the EEG signal has an amplitude in microvolts (µVpp) it is necessary to use amplifiers, leaving the signal possible to be registered. The electrode-electrolyte interface is very important and must be able to provide a good connection between the skin and the conductive material of the electrode, otherwise the EEG signal, in addition to being contaminated by noise, may suffer distortion.

Intervention type: OTHER
Intervention: electroencephalogram
Description: The EEG is the recording of electrical activity in the brain in different regions of the cortex. The capture of electrical signals is performed by attaching electrodes to the surface of the scalp. As the EEG signal has an amplitude in microvolts (µVpp) it is necessary to use amplifiers, leaving the signal possible to be registered. The electrode-electrolyte interface is very important and must be able to provide a good connection between the skin and the conductive material of the electrode, otherwise the EEG signal, in addition to being contaminated by noise, may suffer distortion.
Study: NCT04783051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine pyrimethamine
Description: Intermittent Preventive Treatment in pregnant women with Sulfadoxine-Pyrimethamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyramax
Description: Intermittent screening using ultra-sensitive malaria Rapid Diagnostic test and treatment using Pyronaridine - Artesunate (PYRAMAX®)
Study: NCT06009471

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine treatment in Neurology
Description: Routine treatment in Neurology department, including drug treatment,etc.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Routine treatment in Neurology and rTMS
Description: Add rTMS to routine treatment. Low frequency rTMS is often used to treat cortical hyperexcitability and high frequency rTMS to treat hypoexcitability
Study: NCT06122298

Intervention type: OTHER
Intervention: fMRI
Description: A brain imaging technique that measures in vivo the activity of brain areas by detecting local changes in blood flow.

Intervention type: OTHER
Intervention: fMRI
Description: A brain imaging technique that measures in vivo the activity of brain areas by detecting local changes in blood flow.

Intervention type: OTHER
Intervention: Ecological Momentary Assessment
Description: studies people's thoughts and behaviour in their daily lives by repeatedly collecting data in an individual's normal environment, at or close to the time they carry out that behaviour
Study: NCT04312165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duramesh Laparotomy Closure
Description: Closure of midline laparotomy incision with experimental suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional suture closure
Description: Closure of midline laparotomy incision with standard suture
Study: NCT04862572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI scanning
Description: In the audiological assessment, participants will undergo various audiometric test, such as pure tone audiometry with extended high-frequency range, speech audiometry, tympanometry, and auditory reflex threshold. These tests are all noninvasive and aim to assess participants hearing threshold, speech-in-noise difficulty, whether or not they have conductive hearing loss, and test efferent auditory function. The appointment will take around 60-90 minutes. An experienced audiologist on-site will be in charge of this procedure.~In the MRI appointment, participant will undergo MRI scanning. Before the MRI scan, a researcher with experienced radiographer will re-check that the participant is safe to be scanned, with the standard University of Nottingham safety questionnaire. This rechecking step is necessary to make sure that participants are still eligible for the scanning. An experience radiographer will be in charge of this procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI scanning
Description: In the audiological assessment, participants will undergo various audiometric test, such as pure tone audiometry with extended high-frequency range, speech audiometry, tympanometry, and auditory reflex threshold. These tests are all noninvasive and aim to assess participants hearing threshold, speech-in-noise difficulty, whether or not they have conductive hearing loss, and test efferent auditory function. The appointment will take around 60-90 minutes. An experienced audiologist on-site will be in charge of this procedure.~In the MRI appointment, participant will undergo MRI scanning. Before the MRI scan, a researcher with experienced radiographer will re-check that the participant is safe to be scanned, with the standard University of Nottingham safety questionnaire. This rechecking step is necessary to make sure that participants are still eligible for the scanning. An experience radiographer will be in charge of this procedure.
Study: NCT04814875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
Description: Pegylated liposomal doxorubicin (30 mg/m²) will be administered intravenously on Day 1 of each 28-day cycle; carboplatin (AUC5) will be administered intravenously on Day 1 of each cycle.~ATX-101 will be administered intravenously on Day 2 of each cycle in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
Description: Pegylated liposomal doxorubicin (30 mg/m²) will be administered intravenously on Day 1 of each 28-day cycle; carboplatin (AUC5) will be administered intravenously on Day 1 of each cycle.~ATX-101 will be administered intravenously on Day 2 of each cycle in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design.
Study: NCT05552274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECC4703
Description: ECC4703 will be administered as 1 mg, 10 mg and 40 mg capsules. ECC4703 will be administered as oral capsules during each dosing day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECC4703
Description: ECC4703 will be administered as 1 mg, 10 mg and 40 mg capsules. ECC4703 will be administered as oral capsules during each dosing day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered as oral capsules. Matching Placebo will be given orally during each dosing day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered as oral capsules. Matching Placebo will be given orally during each dosing day.
Study: NCT05982067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness-based phsycial exercise intervention
Description: The intervention is 12 weeks, two times a week. The MIPE intervention will be conducted in a hybrid way, a combination of face-to-face and at home, by a qualified mindfulness therapist and a qualified sport coach. Specifically, the participants will attend the face-to-face sessions once every two weeks and in other weeks, they will perform the intervention at home using videos and templates. The face-to-face sessions will be conducted at the health care centre. The intervention of each session will include 1) introduce the theme of this session, 2) mini lectures about the theme; 3) mindfulness practice related to the theme; 4) tips of keeping mindfulness during PE; 5) warm up: lead with mindfulness words; 6) resistance exercise; 7) cool down: lead with mindfulness words; 8) discussion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: health education
Description: The number of sessions, duration, frequency, group size and delivery modality will be similar to the intervention group. The topics of the health education are the care of common diseases in the older adults, including hypertension, diabetes, osteoporosis, COPD, dementia, depression. Each session is about 70 min (same as intervention group), including 10-20 min lecture and 50-60 discussion and sharing.
Study: NCT05405556

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: eGFR reporting
Description: To test the proportion of patients successfully completing the protocol according to different eGFR reporting strategies, randomization in a 1:1 fashion at the patient level (n=50) will occur as follows:~1. only study-related eGFR values \>25% below baseline will be reported to patients and providers~2. all study-related eGFR will be provided to patients and providers

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: eGFR reporting
Description: To test the proportion of patients successfully completing the protocol according to different eGFR reporting strategies, randomization in a 1:1 fashion at the patient level (n=50) will occur as follows:~1. only study-related eGFR values \>25% below baseline will be reported to patients and providers~2. all study-related eGFR will be provided to patients and providers
Study: NCT06105437

Intervention type: OTHER
Group type: OTHER
Intervention: BE-EMPOWERed program
Description: The BE-EMPOWERed program entails a group program for older people, workshops for healthcare professionals and a 6-steps implementation plan for primary care areas. The group program for older people is based on the main principles of the Australian multifactorial falls prevention program 'Stepping On'. The workshops for healthcare professionals focus on the multifactorial falls prevention approach, reimbursement of healthcare costs, referrals to other healthcare professionals and motivational interviewing. The Implementation plan consists of 6-steps: 1. enable support, 2. map baseline situation, 3. define objectives and priorities, 4. plan implementation, 5. implementation and 6. evaluation, adjust and work towards sustainability. Last, to support the primary care areas, implementation facilitators were trained.
Study: NCT06023407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Immersion Heat Therapy
Description: 10-weeks of 3 days per week in 1 of the 2 arms

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water Immersion Heat Therapy
Description: 10-weeks of 3 days per week in 1 of the 2 arms
Study: NCT05574985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)
Description: Injected one dose of research vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)
Description: Injected one dose of research vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell)
Description: Injected one dose of research vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated COVID-19 vaccine (Vero Cell)
Description: Injected one dose of control vaccine